The HA-1A saga: The scientific and ethical dilemma of innovative and costly therapies
- 1 May 1994
- journal article
- Published by Springer Nature in Intensive Care Medicine
- Vol. 20 (5) , 314-316
- https://doi.org/10.1007/bf01720901
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- HA-1A in septic patients with ARDS: Results from the pivotal trialIntensive Care Medicine, 1994
- Introduction of new technology into critical care practiceCritical Care Medicine, 1993
- Critical Appraisal of Therapeutic Interventions in the Intensive Care Unit: Human Monoclonal Antibody Treatment in SepsisJournal of Intensive Care Medicine, 1992
- Anti-Endotoxin Monoclonal AntibodiesNew England Journal of Medicine, 1992
- Anti-Endotoxin Monoclonal Antibodies — A Second LookNew England Journal of Medicine, 1992
- Antiendotoxin Monoclonal Antibodies for Gram-Negative Sepsis: Guidelines from the IDSAClinical Infectious Diseases, 1992
- Cost-effectiveness of HA-1A Monoclonal Antibody for Gram-Negative SepsisPublished by American Medical Association (AMA) ,1991
- Monoclonal Antibodies to Endotoxin New Allies Against Sepsis?Published by American Medical Association (AMA) ,1991
- Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against EndotoxinNew England Journal of Medicine, 1991
- The Regulation of Investigational DrugsNew England Journal of Medicine, 1989